Approvals: Novartis’ Silver Lining

October 1, 2001
Kevin Gopal
Kevin Gopal

Kevin Gopal is Pharmaceutical Executive's international correspondent, covering pharma and regulatory issues around the word. He is also a political columnist for North West Business Insider, one of the UK's leading regional business magazines. He started his career as a journalist at SiYu, the UK's Chinese community magazine, before joining the PE staff.

Pharmaceutical Executive

Pharmaceutical Executive, Pharmaceutical Executive-10-01-2001, Volume 0, Issue 0

Basel-A series of product approvals in recent weeks could go some way to compensate for setbacks in Novartis’ pipeline. The approvals came as the Swiss company reported healthy half-year figures and an 11 percent sales increase.

Related Content:

News